Home Featured Page 250

Featured

Latest

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update

More than 80% of Americans report one or more symptoms of...

The Impact of Specific Genes on Cannabis Use Disorder

IntelGenx Announces Initial Closing of atai Investment

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop...

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture...

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug...

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of...

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase...

BetterLife Announces Closing of a Non-Brokered Private Placement

1...249250251...299 Page 250 of 299

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update

More than 80% of Americans report one or more symptoms of...

The Impact of Specific Genes on Cannabis Use Disorder

IntelGenx Announces Initial Closing of atai Investment

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop...

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture...

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug...

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of...

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase...

BetterLife Announces Closing of a Non-Brokered Private Placement

EDITOR PICKS

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY